BR112017026159A2 - inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer - Google Patents

inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer

Info

Publication number
BR112017026159A2
BR112017026159A2 BR112017026159-6A BR112017026159A BR112017026159A2 BR 112017026159 A2 BR112017026159 A2 BR 112017026159A2 BR 112017026159 A BR112017026159 A BR 112017026159A BR 112017026159 A2 BR112017026159 A2 BR 112017026159A2
Authority
BR
Brazil
Prior art keywords
compounds
erk1
heterocyclic
cancer treatment
erk2 inhibitors
Prior art date
Application number
BR112017026159-6A
Other languages
English (en)
Inventor
M. Venkatesan Aranapakam
K. Thompson Scott
A. Smith Roger
P. REDDY Sanjeeva
M. DEWANG Purushottam
Hallur Gurulingappa
Mulakala Chandrika
Reddy Kethiri Raghava
Mullangi Ramesh
Zainuddin Mohd
Original Assignee
Asana Biosciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences, Llc filed Critical Asana Biosciences, Llc
Publication of BR112017026159A2 publication Critical patent/BR112017026159A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se a novos compostos heterocíclicos e sais farmaceuticamente aceitáveis dos mesmos. também são providos métodos para preparar esses compostos. esses compostos são úteis para inibir erk1/2. com a administração a um paciente que necessita de uma quantidade terapeuticamente eficaz de um ou mais dos compostos de fórmula (i), em que x, y, z, j, m e r1 a r8 são definidos no presente documento, esses compostos são eficazes no tratamento de condições associadas com a desregulação da via ras/raf/mek/erk. uma variedade de condições pode ser tratada usando esses compostos e inclui doenças que são caracterizadas por proliferação celular anormal. em uma modalidade, a doença é câncer.
BR112017026159-6A 2015-06-15 2016-06-15 inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer BR112017026159A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562175756P 2015-06-15 2015-06-15
US62/175,756 2015-06-15
PCT/US2016/037697 WO2016205418A1 (en) 2015-06-15 2016-06-15 Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112017026159A2 true BR112017026159A2 (pt) 2018-08-14

Family

ID=56497830

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017026159-6A BR112017026159A2 (pt) 2015-06-15 2016-06-15 inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer

Country Status (18)

Country Link
US (5) US10751332B2 (pt)
EP (2) EP3842429B1 (pt)
JP (2) JP6909729B2 (pt)
KR (2) KR102644798B1 (pt)
CN (2) CN107922387A (pt)
AU (2) AU2016280717C1 (pt)
BR (1) BR112017026159A2 (pt)
CA (1) CA2986587C (pt)
DK (2) DK3842429T3 (pt)
ES (2) ES2968007T3 (pt)
FI (1) FI3307727T3 (pt)
IL (1) IL255613B (pt)
MX (2) MX2017014584A (pt)
PL (1) PL3842429T3 (pt)
PT (2) PT3842429T (pt)
RU (1) RU2017139727A (pt)
WO (1) WO2016205418A1 (pt)
ZA (1) ZA201707526B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842429B1 (en) 2015-06-15 2022-09-07 Asana BioSciences, LLC Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer
MX2018004643A (es) 2015-10-21 2018-08-01 Otsuka Pharma Co Ltd Compuestos de benzolactama como inhibidores de la proteina cinasa.
GB201706327D0 (en) * 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
US20210085663A1 (en) * 2017-05-16 2021-03-25 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
JP2021525783A (ja) * 2018-06-08 2021-09-27 貝達薬業股▲ふん▼有限公司Ｂｅｔｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．，Ｌｔｄ Ｅｒｋ阻害剤及びその使用
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
TW202102511A (zh) 2019-03-28 2021-01-16 大陸商江蘇恆瑞醫藥股份有限公司 噻吩并雜環類衍生物、其製備方法及其在醫藥上的應用
JP2022528083A (ja) * 2019-03-29 2022-06-08 ジエンス ヘンルイ メデイシンカンパニー リミテッド ピロロ複素環式誘導体、この誘導体のための調製方法及び医学におけるこの誘導体の用途
EP4051264A1 (en) * 2019-10-28 2022-09-07 Asana BioSciences, LLC Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2
CN111620860B (zh) * 2020-06-23 2023-02-03 济南健丰化工有限公司 一种福瑞塞替的制备方法
CN114315837B (zh) * 2020-09-29 2023-06-16 江苏恒瑞医药股份有限公司 一种erk抑制剂的结晶形式及其制备方法
US20230331731A1 (en) * 2020-09-29 2023-10-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal form of pyrrolo heterocyclic derivative and preparation method therefor
US20240207269A1 (en) * 2021-04-16 2024-06-27 Erasca, Inc. Uses of heterocyclic inhibitors of erk1/2
TW202317122A (zh) * 2021-06-24 2023-05-01 美商艾瑞斯卡公司 Erk1/2及kras g12c抑制劑之組合療法
TW202317123A (zh) * 2021-06-24 2023-05-01 美商艾瑞斯卡公司 Erk1/2及cdk4/6抑制劑之組合療法
CA3222772A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Erk1/2 and shp2 inhibitors combination therapy
WO2022271919A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy
TW202341999A (zh) * 2022-03-28 2023-11-01 大陸商江蘇恒瑞醫藥股份有限公司 吡咯并雜環類衍生物的富馬酸鹽的晶型及其製備方法
WO2024064690A1 (en) * 2022-09-20 2024-03-28 Erasca, Inc. Erk1/2 inhibitor polymorph forms

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319849B1 (it) 2000-02-18 2003-11-03 Angelo Dotta Cerotto in confezione ad apertura rapida e mezzi per la realizzazionedella stessa.
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6743941B2 (en) 2001-06-15 2004-06-01 Aventis Pharma Deutschland Gmbh Process for the production of piperidine derivatives
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
AU2004313928A1 (en) * 2003-12-02 2005-07-28 Vertex Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors and uses thereof
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
UA84929C2 (en) * 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
US7501415B2 (en) * 2004-12-23 2009-03-10 Vertex Pharmaceuticals Incorporated Selective inhibitors of ERK protein kinase and uses thereof
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
EA024729B1 (ru) * 2009-11-13 2016-10-31 Джиноско Киназные ингибиторы
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
EP3842429B1 (en) 2015-06-15 2022-09-07 Asana BioSciences, LLC Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer
TW201805000A (zh) 2016-06-20 2018-02-16 庫拉腫瘤技術股份有限公司 利用erk抑制劑之鱗狀細胞癌之治療
WO2020046966A1 (en) 2018-08-27 2020-03-05 Kura Oncology, Inc. Treatment of adenocarcinomas with mapk pathway inhibitors
EP4051264A1 (en) 2019-10-28 2022-09-07 Asana BioSciences, LLC Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2
US20240207269A1 (en) 2021-04-16 2024-06-27 Erasca, Inc. Uses of heterocyclic inhibitors of erk1/2

Also Published As

Publication number Publication date
US20170362216A1 (en) 2017-12-21
CN113200961B (zh) 2023-12-22
AU2016280717A1 (en) 2017-12-21
FI3307727T3 (fi) 2024-01-08
US9896445B2 (en) 2018-02-20
DK3307727T3 (da) 2024-01-08
AU2016280717B2 (en) 2020-12-03
IL255613A (en) 2018-01-31
KR20210022160A (ko) 2021-03-02
KR20180014706A (ko) 2018-02-09
AU2020273302B2 (en) 2022-08-11
AU2016280717C1 (en) 2021-05-13
CA2986587C (en) 2024-03-12
WO2016205418A1 (en) 2016-12-22
ES2930050T3 (es) 2022-12-05
US11103491B2 (en) 2021-08-31
KR102644788B1 (ko) 2024-03-08
US11925629B2 (en) 2024-03-12
AU2020273302A1 (en) 2020-12-17
PL3842429T3 (pl) 2023-02-20
CN107922387A (zh) 2018-04-17
MX2017014584A (es) 2018-02-26
US10751332B2 (en) 2020-08-25
JP2018517685A (ja) 2018-07-05
PT3307727T (pt) 2024-01-12
EP3307727B1 (en) 2023-10-04
JP7093438B2 (ja) 2022-06-29
ES2968007T3 (es) 2024-05-06
JP6909729B2 (ja) 2021-07-28
PT3842429T (pt) 2022-11-21
RU2017139727A (ru) 2019-07-16
CN113200961A (zh) 2021-08-03
EP3842429B1 (en) 2022-09-07
US20200179356A1 (en) 2020-06-11
EP3842429A1 (en) 2021-06-30
CA2986587A1 (en) 2016-12-22
DK3842429T3 (da) 2022-11-07
IL255613B (en) 2021-03-25
US10471051B2 (en) 2019-11-12
US20230051842A1 (en) 2023-02-16
KR102644798B1 (ko) 2024-03-08
MX2021000148A (es) 2021-03-25
JP2021105004A (ja) 2021-07-26
EP3307727A1 (en) 2018-04-18
US20160362406A1 (en) 2016-12-15
ZA201707526B (en) 2018-11-28
US20160362407A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112019007144A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
BR112018000808A2 (pt) compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
BR112014028954A2 (pt) amidas de n-piridinila substituídas no anel como inibidores da quinase
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
EA201792116A1 (ru) Ингибитор янус-киназы
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112015021549A2 (pt) inibidores de piridina cinase cdk9
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]